Lay summary
In recent years, there has been a growing interest in molecular targeted therapies to treat cancer, such as antibody-drug conjugates (ADCs). These innovative therapies combine the specificity of monoclonal antibodies (mAbs) with the cytotoxicity of small molecule drugs, resulting in greater efficacy and tolerability compared to systemic chemotherapies. Despite the success of ADCs in treating both solid and haematological cancers, resistance and tumour heterogeneity remain significant factors contributing to treatment failure. To address this clinical challenge, our aim is to develop a homogeneous ADC that directly delivers two drugs with distinct mechanisms of action to cancer cells. The focus of this intervention will be on ovarian cancer, the least researched cancer in the country. In New Zealand alone, approximately 300 women are diagnosed with ovarian cancer each year, and despite advancements, survival rates remain unchanged, highlighting the urgent need for effective interventions.